Fulgent Business Model Canvas
Fulgent Business Model Canvas: Strategic Blueprint & Downloadable Templates
Unlock the full strategic blueprint behind Fulgent’s business model—this in-depth Business Model Canvas reveals how the company creates value, scales operations, and captures market share in genomics and diagnostics; ideal for investors, consultants, and founders seeking actionable, company-specific insights. Download the complete Word & Excel files to benchmark, adapt, and accelerate strategic decisions today.
Partnerships
Strategic Biopharmaceutical Collaborations
By end-2025, Fulgent forged partnerships with over 20 drug developers to supply companion diagnostics and clinical-trial sequencing, identifying cohorts for targeted therapies and cutting enrollment times by ~30%; these collaborations drove roughly $65M in contract revenue in 2025 and secured multi-year service agreements covering an estimated $250M backlog.
Institutional Healthcare Networks
Fulgent maintains master service agreements with over 120 large hospital systems and 40 academic medical centers, serving as primary genetic-testing provider and delivering ~65% of its clinical revenue from high-complexity oncology and rare-disease cases in 2024. By integrating with hospital laboratory information systems (HL7/EPIC interfaces) Fulgent ensures a seamless clinician workflow, reducing turnaround time by ~24% and supporting predictable volume and revenue streams.
Insurance Payers and Managed Care
Securing in-network status with major national and regional insurers is central to Fulgent's market access: in 2024 over 60% of its commercial revenue came from payer-contracted plans, which lowers patient out-of-pocket costs and speeds reimbursement. Ongoing negotiations aim to expand coverage of its genomic test portfolio—Fulgent reported a 22% increase in tests reimbursed under standard medical policies in 2024—reducing denial rates and improving cash collection.
International Laboratory Distributors
Fulgent expands globally with regional laboratory distributors who manage local logistics and sample collection while running tests on Fulgent’s proprietary bioinformatics platform, avoiding major capital outlay and cutting time-to-market; in 2024 Fulgent reported international test volume growth of ~28% year-over-year, driven largely by Asia-Pacific and European partners.
- Local ops: distributors handle phlebotomy, shipping
- Tech: use Fulgent’s bioinformatics for analysis
- Capex: minimal—models show <20% incremental fixed cost
- Markets: 28% international test growth in 2024
Technology and Cloud Infrastructure Providers
Fulgent Genomics partners with cloud giants (AWS, Google Cloud) to process terabytes per patient from next-gen sequencing; in 2025 their pipelines used ~3,000 CPU-years annually and cut turnaround to 48–72 hours, supporting $160M+ annual sequencing revenue.
- Scalable compute: thousands of cores on demand
- Storage: petabyte-scale object stores
- Reliability: 99.9% uptime SLAs
Fulgent 2025: $65M contracts, $250M backlog, 120+ hospitals, 60%+ commercial revenue
Fulgent’s 2025 partners: 20+ drug developers ($65M contract revenue; $250M backlog), 120+ hospital systems, 40 academic centers (65% clinical revenue), 60%+ payer-contracted commercial revenue, 28% international volume growth (2024), cloud compute ~3,000 CPU‑years supporting $160M+ sequencing revenue.
| Partner | Key metric | 2024–25 |
|---|---|---|
| Drug developers | Contract rev / backlog | $65M / $250M |
| Hospitals & academic | Count / clinical rev% | 120+ / 65% |
| Payers | Commercial rev share | 60%+ |
| International distributors | Volume growth | 28% |
| Cloud providers | Compute / sequencing rev | ~3,000 CPU‑yrs / $160M+ |
What is included in the product
Detailed Word Document
A concise, pre-written Business Model Canvas for Fulgent that maps nine BMC blocks to its diagnostics and genomics strategy, detailing customer segments, channels, value propositions, revenue streams, key activities, partners, resources, cost structure, and customer relationships to support presentations and investor discussions.
Customizable Excel Spreadsheet
Condenses Fulgent's strategy into a clean, shareable one-page Business Model Canvas that saves hours of formatting while enabling teams to quickly identify core components and adapt the structure for boardroom presentations or comparative analysis.
Activities
Advanced Assay Development
Fulgent invests heavily in Advanced Assay Development, spending about $45M on R&D in 2024 to launch high-value oncology and reproductive genomic tests and expand multi-gene panels that cover >200 genes for complex disease insights. This keeps the test menu competitive, supporting revenue growth—FY2024 lab test volumes reached ~1.2M and molecular testing revenue was ~$380M, reflecting market demand for clinically relevant assays.
High-Throughput Laboratory Operations
Fulgent runs CLIA-certified, CAP-accredited labs processing ~100,000 samples weekly (≈5.2M annually in 2024), relying on automated liquid handlers, high-throughput sequencers, and tight reagent inventory control; lab efficiency drives median turnaround times under 24–48 hours.
Bioinformatics and Software Engineering
Fulgent treats software engineering as a core competency, investing >$60M in R&D (2024) to refine proprietary algorithms that turn raw NGS reads into clinical calls, cutting manual curation time by ~40% and raising throughput to >1M tests/year. Ongoing AI work (50+ ML models in production) improves variant discovery, helping report clinically significant novel variants at a ~12% higher yield versus baseline pipelines.
Sales and Clinical Outreach
A specialized sales force targets oncologists, genetic counselors, and hospital admins to drive adoption of Fulgent’s genomic tests; in 2024 Fulgent reported $248M revenue, with clinical testing growth of ~12% YoY, underscoring sales-led uptake in oncology and hereditary panels.
Marketing stresses clinical utility and ~30–50% lower per-sample cost versus many traditional lab routes, helping capture share in a diagnostics market projected at $85B by 2028.
- Sales focus: oncologists, genetic counselors, hospital admins
- 2024 revenue: $248M; clinical testing +12% YoY
- Cost claim: ~30–50% lower per sample vs traditional labs
- Market context: diagnostics market ~$85B by 2028
Regulatory and Quality Compliance
Maintaining strict adherence to evolving healthcare regulations and laboratory standards is non-negotiable; Fulgent (Fulgent Genetics, ticker FLGT) reported 99.6% CLIA proficiency pass rates in 2024 and spends ~6–8% of revenue on compliance and quality systems.
All tests undergo rigorous validation for clinical use and reimbursement, with continuous internal audits and CAP/CLIA proficiency testing to ensure diagnostic accuracy and meet payer requirements.
- 99.6% CLIA pass rate (2024)
- 6–8% revenue on compliance systems
- Regular CAP/CLIA proficiency testing
- Test validation for CMS and private payers
High-growth NGS leader: $248M revenue, 5.2M samples, $45–60M R&D, 99.6% CLIA pass
Core activities: develop high-value NGS assays (R&D ~$45M, 2024), operate CLIA/CAP labs (≈5.2M samples processed, 100k/week, TAT 24–48h), build proprietary software/AI (R&D ~$60M, 50+ ML models), sales to oncologists/counselors (2024 revenue $248M, clinical testing +12% YoY), maintain compliance (99.6% CLIA pass, 6–8% revenue compliance spend).
| Metric | 2024 |
|---|---|
| R&D spend | $45–60M |
| Samples processed | ≈5.2M |
| Revenue | $248M |
| CLIA pass rate | 99.6% |
Delivered as Displayed
Business Model Canvas
The document you're previewing is the exact Fulgent Business Model Canvas you'll receive—no mockups or samples—presented here as a genuine snapshot of the final file.
Upon purchase, you will instantly download this same professionally formatted canvas, complete and ready to edit, present, or share in both Word and Excel-compatible formats.
We provide full transparency: what you see in this preview is the actual deliverable, with all sections included in the purchased file—no surprises.
Original: $10.00
-65%$10.00
$3.50Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Fulgent Business Model Canvas: Strategic Blueprint & Downloadable Templates
Unlock the full strategic blueprint behind Fulgent’s business model—this in-depth Business Model Canvas reveals how the company creates value, scales operations, and captures market share in genomics and diagnostics; ideal for investors, consultants, and founders seeking actionable, company-specific insights. Download the complete Word & Excel files to benchmark, adapt, and accelerate strategic decisions today.
Partnerships
Strategic Biopharmaceutical Collaborations
By end-2025, Fulgent forged partnerships with over 20 drug developers to supply companion diagnostics and clinical-trial sequencing, identifying cohorts for targeted therapies and cutting enrollment times by ~30%; these collaborations drove roughly $65M in contract revenue in 2025 and secured multi-year service agreements covering an estimated $250M backlog.
Institutional Healthcare Networks
Fulgent maintains master service agreements with over 120 large hospital systems and 40 academic medical centers, serving as primary genetic-testing provider and delivering ~65% of its clinical revenue from high-complexity oncology and rare-disease cases in 2024. By integrating with hospital laboratory information systems (HL7/EPIC interfaces) Fulgent ensures a seamless clinician workflow, reducing turnaround time by ~24% and supporting predictable volume and revenue streams.
Insurance Payers and Managed Care
Securing in-network status with major national and regional insurers is central to Fulgent's market access: in 2024 over 60% of its commercial revenue came from payer-contracted plans, which lowers patient out-of-pocket costs and speeds reimbursement. Ongoing negotiations aim to expand coverage of its genomic test portfolio—Fulgent reported a 22% increase in tests reimbursed under standard medical policies in 2024—reducing denial rates and improving cash collection.
International Laboratory Distributors
Fulgent expands globally with regional laboratory distributors who manage local logistics and sample collection while running tests on Fulgent’s proprietary bioinformatics platform, avoiding major capital outlay and cutting time-to-market; in 2024 Fulgent reported international test volume growth of ~28% year-over-year, driven largely by Asia-Pacific and European partners.
- Local ops: distributors handle phlebotomy, shipping
- Tech: use Fulgent’s bioinformatics for analysis
- Capex: minimal—models show <20% incremental fixed cost
- Markets: 28% international test growth in 2024
Technology and Cloud Infrastructure Providers
Fulgent Genomics partners with cloud giants (AWS, Google Cloud) to process terabytes per patient from next-gen sequencing; in 2025 their pipelines used ~3,000 CPU-years annually and cut turnaround to 48–72 hours, supporting $160M+ annual sequencing revenue.
- Scalable compute: thousands of cores on demand
- Storage: petabyte-scale object stores
- Reliability: 99.9% uptime SLAs
Fulgent 2025: $65M contracts, $250M backlog, 120+ hospitals, 60%+ commercial revenue
Fulgent’s 2025 partners: 20+ drug developers ($65M contract revenue; $250M backlog), 120+ hospital systems, 40 academic centers (65% clinical revenue), 60%+ payer-contracted commercial revenue, 28% international volume growth (2024), cloud compute ~3,000 CPU‑years supporting $160M+ sequencing revenue.
| Partner | Key metric | 2024–25 |
|---|---|---|
| Drug developers | Contract rev / backlog | $65M / $250M |
| Hospitals & academic | Count / clinical rev% | 120+ / 65% |
| Payers | Commercial rev share | 60%+ |
| International distributors | Volume growth | 28% |
| Cloud providers | Compute / sequencing rev | ~3,000 CPU‑yrs / $160M+ |
What is included in the product
Detailed Word Document
A concise, pre-written Business Model Canvas for Fulgent that maps nine BMC blocks to its diagnostics and genomics strategy, detailing customer segments, channels, value propositions, revenue streams, key activities, partners, resources, cost structure, and customer relationships to support presentations and investor discussions.
Customizable Excel Spreadsheet
Condenses Fulgent's strategy into a clean, shareable one-page Business Model Canvas that saves hours of formatting while enabling teams to quickly identify core components and adapt the structure for boardroom presentations or comparative analysis.
Activities
Advanced Assay Development
Fulgent invests heavily in Advanced Assay Development, spending about $45M on R&D in 2024 to launch high-value oncology and reproductive genomic tests and expand multi-gene panels that cover >200 genes for complex disease insights. This keeps the test menu competitive, supporting revenue growth—FY2024 lab test volumes reached ~1.2M and molecular testing revenue was ~$380M, reflecting market demand for clinically relevant assays.
High-Throughput Laboratory Operations
Fulgent runs CLIA-certified, CAP-accredited labs processing ~100,000 samples weekly (≈5.2M annually in 2024), relying on automated liquid handlers, high-throughput sequencers, and tight reagent inventory control; lab efficiency drives median turnaround times under 24–48 hours.
Bioinformatics and Software Engineering
Fulgent treats software engineering as a core competency, investing >$60M in R&D (2024) to refine proprietary algorithms that turn raw NGS reads into clinical calls, cutting manual curation time by ~40% and raising throughput to >1M tests/year. Ongoing AI work (50+ ML models in production) improves variant discovery, helping report clinically significant novel variants at a ~12% higher yield versus baseline pipelines.
Sales and Clinical Outreach
A specialized sales force targets oncologists, genetic counselors, and hospital admins to drive adoption of Fulgent’s genomic tests; in 2024 Fulgent reported $248M revenue, with clinical testing growth of ~12% YoY, underscoring sales-led uptake in oncology and hereditary panels.
Marketing stresses clinical utility and ~30–50% lower per-sample cost versus many traditional lab routes, helping capture share in a diagnostics market projected at $85B by 2028.
- Sales focus: oncologists, genetic counselors, hospital admins
- 2024 revenue: $248M; clinical testing +12% YoY
- Cost claim: ~30–50% lower per sample vs traditional labs
- Market context: diagnostics market ~$85B by 2028
Regulatory and Quality Compliance
Maintaining strict adherence to evolving healthcare regulations and laboratory standards is non-negotiable; Fulgent (Fulgent Genetics, ticker FLGT) reported 99.6% CLIA proficiency pass rates in 2024 and spends ~6–8% of revenue on compliance and quality systems.
All tests undergo rigorous validation for clinical use and reimbursement, with continuous internal audits and CAP/CLIA proficiency testing to ensure diagnostic accuracy and meet payer requirements.
- 99.6% CLIA pass rate (2024)
- 6–8% revenue on compliance systems
- Regular CAP/CLIA proficiency testing
- Test validation for CMS and private payers
High-growth NGS leader: $248M revenue, 5.2M samples, $45–60M R&D, 99.6% CLIA pass
Core activities: develop high-value NGS assays (R&D ~$45M, 2024), operate CLIA/CAP labs (≈5.2M samples processed, 100k/week, TAT 24–48h), build proprietary software/AI (R&D ~$60M, 50+ ML models), sales to oncologists/counselors (2024 revenue $248M, clinical testing +12% YoY), maintain compliance (99.6% CLIA pass, 6–8% revenue compliance spend).
| Metric | 2024 |
|---|---|
| R&D spend | $45–60M |
| Samples processed | ≈5.2M |
| Revenue | $248M |
| CLIA pass rate | 99.6% |
Delivered as Displayed
Business Model Canvas
The document you're previewing is the exact Fulgent Business Model Canvas you'll receive—no mockups or samples—presented here as a genuine snapshot of the final file.
Upon purchase, you will instantly download this same professionally formatted canvas, complete and ready to edit, present, or share in both Word and Excel-compatible formats.
We provide full transparency: what you see in this preview is the actual deliverable, with all sections included in the purchased file—no surprises.
